Table_1_The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.DOCX

IntroductionShufeng Jiedu capsule (SFJD) is a commonly used Chinese patent medicine in China. Some studies have reported that SFJD has therapeutic effects in patients diagnosed with COVID-19. This systematic review aimed to critically evaluate the efficacy and safety of SFJD combined with western medicine (WM) for treating COVID-19.
MethodsA literature search by using WHO COVID-19 database, PubMed, Embase, Cochrane Library, the Web of Science, CKNI, Wanfang, VIP, SinoMed, and clinical trial registries was conducted, up to 1 August 2022. Randomized controlled trials (RCTs), non-RCTs, cohort studies and case series of SFJD combined with WM for COVID-19 were included. Literature screening, data extraction, and quality assessment were performed independently by two reviewers in line with the same criteria. We used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) to assess the certainty of evidence. Meta-analyses were performed with Revman 5.3 if possible. The descriptive analysis was conducted when the studies could not be meta-analyzed.
ResultsTotally 10 studies with 1,083 patients were included. Their methodological quality were moderate. The results demonstrated that compared to WM group, SFJD + WM group remarkably increased the nucleic acid negative conversion rate (RR = 1.40, 95%CI: 1.07–1.84), total effective rate (RR = 1.18, 95%CI: 1.07–1.31), cure rate (RR = 4.06, 95%CI: 2.19–7.53), and the chest CT improvement rate (RR = 1.19, 95%CI: 1.08–1.31), shorten nucleic acid negative conversion time (MD = −0.70, 95%CI: −1.14 to −0.26), reduced the clinical symptom disappearance time (fever, diarrhea, cough, fatigue, pharyngalgia, nasal congestion, and rhinorrhea), as well as improved the levels of laboratory outcomes (CRP, IL-6, Lym, and Neu). Additionally, the incidence of adverse reactions did not exhibit any statistically significant difference between SFJD + WM group and WM group.
ConclusionSFJD combined with WM seems more effective than WM alone for the treatment of COVID-19. However, more well-designed RCTs still are warranted.
Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022306307].

引言
疏风解毒胶囊（Shufeng Jiedu Capsule, SFJD）是我国临床常用的中成药。已有研究报道其对新型冠状病毒肺炎（COVID-19）确诊患者具有治疗效用。本系统综述旨在严格评价疏风解毒胶囊联合西药（Western Medicine, WM）治疗新型冠状病毒肺炎的疗效与安全性。

方法
本研究检索了截至2022年8月1日的WHO COVID-19数据库、PubMed、Embase、Cochrane图书馆、Web of Science、CKNI、万方、维普、SinoMed及临床试验注册平台。纳入疏风解毒胶囊联合西药治疗新型冠状病毒肺炎的随机对照试验（Randomized Controlled Trials, RCTs）、非随机对照试验、队列研究及病例系列研究。由2名评价者按照统一标准独立完成文献筛选、数据提取与质量评价。本研究采用推荐分级、评估、制定与评价（Grading of Recommendations, Assessment, Development, and Evaluations, GRADE）方法对证据确定性进行评级。若条件允许，采用RevMan 5.3软件开展Meta分析；若无法进行Meta分析，则采用描述性分析。

结果
最终纳入10项研究，共计1083例患者，其方法学质量为中等水平。结果显示，与单纯西药组相比，疏风解毒胶囊联合西药组可显著提升核酸转阴率（相对风险RR=1.40，95%置信区间CI：1.07~1.84）、总有效率（RR=1.18，95%CI：1.07~1.31）、治愈率（RR=4.06，95%CI：2.19~7.53）及胸部CT改善率（RR=1.19，95%CI：1.08~1.31），缩短核酸转阴时间（均数差MD=-0.70，95%CI：-1.14~-0.26），缩短发热、腹泻、咳嗽、乏力、咽痛、鼻塞、流涕等临床症状的消失时间，并改善实验室指标[C反应蛋白（C-reactive protein, CRP）、白细胞介素-6（Interleukin-6, IL-6）、淋巴细胞（Lymphocyte, Lym）、中性粒细胞（Neutrophil, Neu）]水平。此外，疏风解毒胶囊联合西药组与单纯西药组的不良反应发生率无统计学显著差异。

结论
疏风解毒胶囊联合西药治疗新型冠状病毒肺炎的效果似乎优于单纯西药治疗，但仍需开展更多设计严谨的随机对照试验。

系统综述注册信息：https://www.crd.york.ac.uk/PROSPERO/，注册号：CRD42022306307。